NCT07084402

Short-term Bactericidal Effect of Contezolid in MAC-PD

Short-term Bactericidal Effect of Contezolid in Mycobacterium Avium Complex Pulmonary Disease

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 188 (estimated)
• Sponsor: Bin Cao · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.

Conditions

• Mycobacterium Avium Complex Pulmonary Disease

Interventions

Type	Name	Description
DRUG	Contezolid	contezolid 800mg po q12h for 6 months
DRUG	Azithromcyin	azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.
DRUG	Rifampicin (RIF)	rifampicin 600mg po tiw for 6 months.
DRUG	Ethambutol	ethambutol 25mg/kg po tiw for 6 months.

Timeline

• Start date: 2025-07-24
• Primary completion: 2027-07-24
• Completion: 2027-12-31
• First posted: 2025-07-24
• Last updated: 2025-09-18

Locations

3 sites across 1 country: China